Schrodinger, Inc. (SDGR): Total Assets
$726.16M
As of 2025-12-31
$640.39M
As of 2026-06-30
+1.8%
3-year compound annual growth
-0.5%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $726.16M | -11.8% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $823.23M | +2.5% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $802.96M | +16.6% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $688.59M | -9.0% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $756.49M | +1.4% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $746.26M | +380.6% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $155.27M | n/a | 2021-03-04, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $726.16M | -11.8% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $717.90M | -34.2% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $1.14B | -1.0% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $1.56B | +65.7% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $338.02M | -45.1% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $817.15M | +193.0% |
| Harrow, Inc. (HROW) | 2025-12-31 | $399.48M | +2.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $376.56M | +70.6% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $364.39M | -24.7% |
Compare SDGR, ARVN, RCUS, LGND side by side · Screen every company in Pharmaceutical Preparations ↗